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Abstract 
Mitochondrial disorders are recognized in several metabolic and degenerative diseases, aging and cancer. Mitochondrial 
functional deficiency maybe caused by a decrease in the function of complex respiratory enzymes that can inhibit the oxidative 
phosphorylation chain (OXPHOS) for synthesis of ATP. Based on data MITOMAP in 2013, there are 211 of 466 mutations that 
have been reported in coding region. The largest number of mutation located on MT-COI region that have 34mutations. In 
particular, mutations in a subunit of COX have been described associate with various clinical phenotypes. Deficiency of COX is 
one of disorder that often leads to mitochondrial disease. Based on the database, the dominant disease on subunit of COI is 
dominated by prostate cancer. Moreover, the highest probability of mutation to the size of gene located on MT-NDI with 2.83%. 
OXPHOS deficiency which is caused by DNA mitochondrial mutation, mostly appears on subunit ND1. The dominant 
phenotype on subunit of NDI is Leber's hereditary optic neuropathy (LHON) diseases. This study has revealed that mutations in 
mitochondrial DNA were not only associated with predisposition to neuromuscular diseases but also to cancer and optical 
interference. 
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1.  Introduction 
 
     Mitochondria is a sub cellular organelle which is responsible over mostly adenosine triphosphate (ATP) synthesis 
in cell through oxidative phosphorylation (OXPHOS)1. Moreover, mitochondria is an important biochemistry 
pathway, including tricarboxylic acid cycle (TCA) and urea cycle. Mitochondria is also crucial as a regulator of 
apoptosis process2, calcium cytosolic concentration and the central biogenesis of iron-sulphur cluster (Fe-S)1. 
Mitochondria disorder is known as the most significant contribution of metabolism and degenerative diseases, aging 
and cancer3,4,5.  
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     Aging in mitochondrial function is caused by degradation of enzyme complex function in respiratory which is 
able to inhibit OXPHOS reaction in producing ATP, or caused by aggression of free radical, Reactive Oxygen 
Spesies (ROS) in several tissues6. Mutated mitochondrial DNA molecule will be transcribed and translated to obtain 
a damaged subunit protein, resulting in disturbance of electron transfer chain (ETC). This disturbance is not only 
causing a digression of ATP synthesis, but also producing more ROS7.  
   Human mitochondrial genome is composed by two parts; one part consists of coding DNA, 13 mRNA, 2 rRNA 
and 22 tRNA, and the others consist of control region which is responsible over mitochondrial genome expression. 
DNA variation occurs randomly either in coding region or control region during human evolution. This variation is 
inherited by maternal relationship and new variant occur in every branch of population inheritance8,9. Addition in 
various subgroup can be spread widely through population migration into different ethnic groups. During 
asymmetric growth rate of variant in control region, different variant is able to appear in similar cluster with another 
variant in coding region10. Some determinations of mitochondrial DNA haplogroup, initially they are defined by 
variant in coding region which is related with particular human diseases11. However, the individual variant role in 
control region of particular diseases and its effect combination during analysis, is not yet fully discovered12. 
Mitochondrial DNA mutation not only occurs in maternal linkage, but also is accumulated  after cleaving process of 
cells inside body, influenced by growth factor. Somatic mutation of mitochondrial DNA appears as aging signature 
and also important in etiology of particular cancer13.  
     Mitochondrial DNA has high mutation rate and has been classified into three class variants, such as pathogen, 
adaptive, and neutral. Pathogen mutation causes alteration of natural function, and deletion mutation increases in 
heteroplasmy percentage which causing degradation of systematic energy synthesis in cell. Deficiency occurs 
naturally, and mutation is detected rapidly from the population as heredity diseases. Furthermore, lately all deletion 
mutation among population relatively occur. Adaptive mutation in mitochondrial DNA alters natural function but 
this alteration is beneficial in particular environment. Therefore, mutation forms in personal (or homoplasmy) and 
advances in a population with compatible environment. Neutral mutation is accumulated spontaneously, but it 
related to certain mutation which is a characteristic of certain population through this study14.  
     Mitochondrial DNA consists of 37 coding genes, which is the subunit of enzyme complex involved in OXPHOS. 
Mutation in coding region of mitochondrial DNA affects these enzymes complex and obtains oxidative disorders. It 
was found having a relation with clinical overview caused by mitochondrial DNA mutation. Hence, this study was 
done to discover mutation in coding region of mitochondrial DNA and to comprehend the relation of genotype and 
phenotype on that coding region.  
     Latest MITOMAP database arranged with more than 5100 sources. This data related to mitochondrial DNA 
sequent, variant sequent and the wide role of mitochondria in several diseases. These sources can be found based on 
writers and subject of words15.  
     Based on MITOMAP database 2013, there are 446 mitochondrial DNA mutations which associate with 
mitochondrial disease and 211 mutations are in coding region. Based on this data, the mutation mostly appear in 
MT-COI region with total 34 mutations and the greatest potential mutation is in MT-NDI region with the percentage 
is 2.83%. 
     There are several damages of mutations in MT-COI and MT-NDI regions related to mitochondrial diseases. The 
dominant phenotype in MT-COI region is prostate cancer. On the other hand, LHON is a dominant phenotype in 
MT-NDI region. The result of related studies showed that those mutations have predisposition with cancer and 
optical disorders.  
 
2.  Materials and Methods 
 
2.1. Data Collection 
 
     All data of mitochondrial DNA mutation associate with mitochondrial diseases was collected and listed from 
MITOMAP database 2013. In hence, data of mutation in coding region and its related mitochondrial diseases were 
selected and organized into database. Several articles were selected and their data were sorted and listed.  
Collected data of MITOMAP database 2013 was calculated to obtain percentage of total mutation. The selected data 
of mutation in coding region was calculated, both the total number of mutation and the percentage of potential 
mutation. The calculation used the basic mathematics calculation.  
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2.2. Data Analysis  
 
     Final data was analysed to relate with the theoretical materials. The numbers of mutation in each locus was 
sorted, then later on the highest number of mutation and potential mutation were selected to be analysed. The data 
was discovered in associating with several mitochondrial diseases through study literature about mitochondrial 
mutation and diseases.  
 
3.  Results and Discussion 
 
     Mitochondria is an intercellular organelle which is responsible over biologic oxidation of several important 
macromolecules in the last pathway stage of aerobic metabolism in animal and human cell16. If the key chain of 
respiratory component in mitochondria lose or damage, there will be an abnormal sustained effect. It can be 
happened in two phases such as (a) First, there will be no electron, ATP cannot be synthesized effectively and the 
cell will lose the energy for doing normal function. (b) Second, All the later phases will stop, then causing a 
formation of abnormal chemical materials which produce toxic. The products are free radical and exceed metabolic 
product such as excessive lactate acid, it is dangerous. Free radical is a reactive molecule which is able to damage 
DNA and cell membrane through oxidation pathway17.  
   Mitochondria is a framer of almost ROS in imperfect reduction of O2. It occurs because the lack of electron on 
ETC. NaDH: ubiquinone oxidoreductase (complex I) and ubiquinol: cytochrome c oxidoreductase (complex III) 
from ETC are the crucial framer of ROS in mitochondria16. Ubisemiquinone and flavosemiquinone radical and ROS 
are sustainably composed and handed in high relative steady state in mitochondria. Respiratory inhibitor prevent  
electron transfer in complex I and complex III causing the aggression of super oxide and hydrogen peroxide in 
cell17.  
    Normally, respiratory chain in mitochondria produces free radical in low number during ATP synthesis. If there is 
a malfunction in respiratory chain, the production of free radical will increase. It will cause further damage on 
mtDNA, and obtain “vicious cycle”, a damage and produce excessive free radical17.  
     Diseases, caused by mitochondrial DNA, was firstly reported in 198818. and since then more than 300 mutation 
pathogen of mitochondrial DNA were reported19. Mitochondrial DNA pathogen has high variability of phenotype 
and appears in various ages20. The crucial stage of this failed energy synthesis is assumed as the primer consequent 
of general mitochondrial cytophaty in cellular stage3.  
     Pathogen mutation in mitochondria can be differed into three categories: 1. Point mutation in tRNAs, rRNAs or 
in coding gene of protein, 2. Extension of deletion or duplication in mitochondrial DNA and 3. The damage of 
nuclear gene. Point mutation is usually inherited, on the other hand deletion mutation is mostly sporadic. Double 
deletion in mitochondrial DNA was found in patient who possessed Sayre21 and Pearsons syndrome22, in diabetic 
patients23 and normal aging24. 
     In 2013, based on MITOMAP (MITOMAP, 2013)25 database there were 449 mutation, there were reported and 
related to mitochondrial diseases. Then, the mitochondrial DNA mutations in coding region were totally 211 
mutations. The highest number of mutation is in MT-COI region with 33 mutations. Coding region consists of 13 
genes that each of them has different nucleotide number. Potential mutation can be determined by the comparison of 
mutation number and nucleotide number. In this coding region, the greatest probability of mutation was in MT-NDI 
region with percentage of mutation number per nucleotide number in the amount of 2.83%. The data can be seen in 
Table 1.  
     Mutation in coding region of mitochondrial DNA related to several mitochondrial diseases. The dominant 
diseases were different in each region. The relation of genotype and phenotype can be seen in Figure 1. 
    In Figure 1 showed there were three dominant phenotypes appear in every coding region. The phenotypes were 
connected with some mutations causing several mitochondrial diseases. Overall, the most frequently disease is 
LHON disease. The highest percentage of phenotype in MT-COI region belongs to prostate cancer with percentage 
was nearly 52.94%. Moreover, in MT-NDI region, LHON disease comes as number one diseases with the highest 
percentage with 19.4%.  
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             Table 1. The total  number of mutation in mtDNA related with  mitochondrial diseases. 
 
Mutation spot Locus Number of 
Mutation 
Sub-total Number of 
nucleotide 
% mutation 
number / 
nucleotide number 
Coding Region MT-ND1 27 211 954 2.83% 
MT-ND2 14 1041 1.34% 
MT-ND3 3 345 0.86% 
MT-ND4 12 1377 0.87% 
MT-ND4L 4 294 1.36% 
MT-ND5 27 1809 1.49% 
MT-ND6 11 522 2.10% 
MT-CYB 29 1140 2.54% 
MT-CO1 33 1539 2.14% 
MT-CO2 16 681 2.34% 
MT-CO3 13 783 1.66% 
MT-ATP6 18 678 2.65% 
MT-ATP8 4 204 1.96% 
 
 
 
 
Fig. 1. The relation of phenotype and mutation in coding region of mitochondrial DNA. 
 
 
3.1. Mutation in COX Region and Subunit COI 
 
     Isolation of COX deficiency had been reported in several specific region or general Mendelian disorders, 
including Leigh syndrome26. During last 4 years, some mitochondrial DNA mutations in COX gen has been 
identified in patients with different clinical manifestation, generally they showed the uncertain cases27,28,29.  
     This showed that COX mutation had been identified disturbing Fe reduction process, without resulting significant 
damage from another respiratory chain. Although the damage disturb the primary metabolic activity of erythroblast  
(for example heme synthesis), causing the damage through secondary effect of Fe charge, at least it occurs in other 
cell pathway. Based on primary erythropoietic disorders, it is found that the growth erythropoietic colony, burst- 
forming units-erythroid  (BFU-E) and colony-forming units-erythroid (CFU-E), actually have no pair or even 
unpaired, reminding growth of CFU-GM is not significantly reduced, whether both inside granulocyte cells and 
macrophage colony bring the similar mitochondrial DNA mutation30.  
     Based on MITOMAP database  201315, in Table 1 showed that the largest number of mutation located on MT-
COI region which is a part of complex IV with 33 mutations on it. On Table 2, we can see that mutation in MT-COI 
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region directly related to several reported mitochondria diseases. 
      The most frequently appearing diseases related to MT-COI encoded region is prostate cancer. The number 
dominated for almost 52.94% of the total diseases number coming up in MT-COI region.  
 
                               Table 2.  The total number of mtDNA diseases related with MT-COI region.  
 
Locus Type of Diseases Number of 
Diseases 
Sub-total 
MT-COI Prostate Cancer 18  
 
 
 
 
 
             34 
Myogloburina 1 
Neouron Nerves 1 
LHON 2 
EXIT 2 
Epilepsi resistent  1 
Miophaty 1 
MM & Rhabdomiolisis 1 
AISA (anemia) 2 
Multisystem Disorder 1 
MELAS 2 
DEAF 3 
SNHL 
Mild EXIT &MR 
2 
1 
 
 
 
 
Fig. 2. The percentage of phenotypes were caused by mutations in MT-COI region. 
 
 
3.2.  The Relation of Mitochondrial DNA and Cancer 
 
     Mutation in mitochondrial DNA had been found requiring criteria related to pathogen mutation of prostate 
cancer. Focusing on COI gene, it was discovered 11-12% of prostate cancer patients undergoing mutation in COI 
which changes original amino acid sequence, whereas < 2% of uncontrolled cancer and 7.8% of general population 
has COI mutation which changes original amino acid. Four mutations in COI were found in several individual with 
various mitochondrial DNA. Another three tumor containing heteroplasmy COI mutation, one of them is stop codon 
framer. The other tumor has generically inherited mutation in ATP6 region. Thus, either genetic or somatic 
mitochondrial DNA mutation contributes in prostate cancer. Most of discovered tumors produce more ROS, and 
mitochondrial DNA mutations which inhibit OXPHOS, obtain similar aggression of ROS and contribute to 
tumorgenity31.  
     Recent study presented a certain prove about mitochondrial DNA mutation takes an important role in prostate 
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cancer etiology. Prostate cancer has the important functional frequency growth in significant COI mutation, and as 
the starter of prostate cancer cell that inhibits OXPHOS and increase ROS production , and in vivo growth31. Human 
cell has a capacity to compensate partially over complex IV disorders by changing subunit COX subunit. By then, 
biochemistry effect of this partial complex IV can be maintained by changing the gene expression. This result will 
be consistent with the observation, by which prostate cancer has increasing level from nuclear DNA into subunit 
complex IV coding region of mitochondrial DNA32. Moreover, COI mutation is able to inhibit ETC and it can 
enhance mitochondrial ROS production and stimulate cell proliferation33,34.  
 
3.3. Mutation in Complex I Region and NDI Subunit 
 
     Among OXPHOS disorder groups, complex I deficiency is the most frequent region caused by OXPHOS 
dysfunction35. Clinical overview of complex I deficiency is caused by mutation in encoded nuclear DNA subunit, 
generally undergo in infant and child, whereas the symptom of the diseases caused by mitochondrial DNA mutation 
appear in teenager or adults. In other groups, there is a big variability of clinical and interfamilial appearance. 
     Protein NDI takes an important role in molecular enzymology of complex I. It had been identified as binding 
rotenone subunit36, an inhibitor that blocks quinone reductase side37. Recently, it has been concluded that quinone 
reductase side is composed, at least with some part of central protein NDI residue38. The wild hydrophilic loop 
region consist of LEU285 residue. Therefore, the effect of L285P substitution in complex I works randomly, it 
might rearrange allosteric site of quinone reductase or vice versa, changes the compilation of protein NDI and 
another subunit from complex I38.  
    ATP production disturbance is the main consequent of complex I deficiency. Hence, mutation effect in complex I 
function has a significant role in clinical pathogenesis of diseases. For example, complex I is an important part of 
ROS production, and ROS is well known as crucial signalling molecule which influence the communication 
between mitochondria and other parts of subcellular. The study had showed that superoxide production is inverse of 
complex I activity in fibroblast complex I deficiency39. Then fibroblast  with low residue activity increase ROS level 
and fragment mitochondrial morphology40. It showed mitochondrial deficiency is being targeted for autophagic 
destruction or mitophagi41. Potential membrane is reduced in fibroblast complex I deficiency42, and there is linier 
relation between potential membrane and superoxide growth level, derivate of ROS43. Eventually, ATP production 
digression is strongly related to ROS and potential membrane level, it showed that these factors play important 
cumulative role in mediating pathogenesis44.  
     Based on MITOMAP database 201325 on Table 2, it had been discovered that the largest probability of mutation 
in coding region located on MT-NDI region which was part of complex I with percentage around 2.83%. Based on 
data in Table 3. MT-NDI mutation related to several reported mitochondrial diseases.  
  The most appearing diseases related to MT-NDI coding region was LHON. The percentage was 19.4% of the total 
number. The percentage of the appearing diseases in MT-NDI can be seen in Figure 3. 
 
 
 
Fig. 3. The percentage of phenotypes were caused by mutations in MT-NDI region. 
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                              Table 3. The total number of mtDNA diseases related to MT-NDI region. 
 
Locus Type of Diseases Number of 
Diseases 
Sub-total 
MT-NDI LHON 7  
 
 
 
 
 
 
 
 
32 
MELAS 5 
HCM 4 
NIDDM 1 
Sudden infant death 1 
ADPD 1 
LVNC 1 
DMDF + HCM 1 
GDM 1 
AMegL 1 
MIDD 1 
BD 1 
Adult-onset dystonia 
PEG 
LS 
Hyptonia 
Seizure 
Develompmental Delay 
1 
1 
2 
1 
1 
1 
 
 
3.4. The Relation of Mitochondrial DNA Mutation and LHON 
 
     Mutation in mitochondrial DNA is a basic molecular of this disease13. There are several mutations involving 
subunit complex I coding region of respiratory chain, counted around 90% of LHON genealogy in some countries45. 
The lingkage of LHON and mitochondrial DNA mutation occurs in almost heteroplasmy and homoplasmy ways. 
Specific characteristic of LHON, carried by mitochondrial DNA mutation, are imperfect penetration and boys are 
usually as the subject of this effect. It figured the complex etiology of this disease46. The main disorder of this 
mutation appears because of the failures in NADH dehydrogenase activity47. Thus it directs to deficiency of 
OXPHOS function and ATP synthesis, and aggression of ROS level. Then the failure of energy synthesis and the 
aggression of oxidative disorder cause degeneration of retinal ganglion cells48.  
     There is a significant correlation between all respiratory capacity or influential level of NADH dehydrogenase or 
succinate/glycerol-3-phosphate (G3P), a promoter in respiratory process, ATP production level, ROS production 
and mutant cell rate. Moreover, mutation results a disturbance of ubiquinone binding in complex I, as the cause of 
several LHON diseases49.  
 
Conclusion 
     Regarding to MITOMAP database 2013, there were 446 mitochondrial mutations related to mitochondrial 
diseases with the total mutation in coding region were 211 mutations. The largest number of mutation located on 
MT-COI region with 34 mutations. Then the biggest probability of mutation to the size of gene located on MT-NDI 
with 2.83%. Based on the data, it showed the linkage of genotype and phenotype, such as the effect of mutation 
located on MT-COI and MT-NDI causes prostate cancer and LHON with each percentage were 52.94% and 19.4%. 
It discovered the relationship of mitochondrial DNA mutation in MT-COI and MT-NDI, which is not only 
associated to predisposition on neuromuscular diseases, but also on cancer and optical diseases.  
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